📰 Quality Considerations News
Quality Considerations News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Quality Considerations. Real-time updates on events, politics, business and more.
January 27, 2024
The last decade has seen a “dramatic increase” in investigational new drug (IND) applications for cannabis-derived products, according to the U.S. Food and Drug Administration.
December 5, 2023
Are your blog images Pinterest-ready? How many times have you found yourself scrolling through Pinterest and coming across an image that just speaks to you? This is the power of perfectly sized and optimized images. Let’s look at how to create visuals that Pinterest users will enjoy.What are the best ways to highlight your blog […]
November 3, 2023
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50
March 21, 2023
Rapid Therapeutics Science Laboratories (OTC: RTSL) ("Rapid Therapeutic or the "Company"), a growth-oriented aerosol manufacturing company focused on natural
March 21, 2023
Rapid Therapeutics Science Laboratories RTSL ("Rapid Therapeutic or the "Company"), a growth-oriented aerosol manufacturing company focused on natural relief
February 1, 2023
The FDA has announced the availability of a guidance for industry entitled ‘‘Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research.’’
January 30, 2023
Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...
January 27, 2023
The FDA announced new guidance entitled Cannabis and Cannabis-Derived Compounds; Quality Considerations for Clinical Research. Those involved in the clinical research of cannabis can rely on this FDA guidance for recommended sources of cannabis for clinical research and resources.
January 26, 2023
FDA issued its final guidance, Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research. The agency outlines current recommendations for drug sponsors developing cannabis and cannabis-derived compounds for use in human drug clinical research.
January 26, 2023
On January 23, 2023, the U.S. Food and Drug Administration (FDA) issued its final guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research” (the...